Loading…

Loading grant details…

Completed HORIZON European Commission

A combined diagnostic and targeted gene therapy platform for brain tumor relapse


Funder European Commission
Recipient Organization Uppsala Universitet
Country Sweden
Start Date Sep 01, 2022
End Date Feb 29, 2024
Duration 546 days
Number of Grantees 2
Roles Participant; Coordinator
Data Source European Commission
Grant ID 101069289
Grant Description

Emergence of therapy resistance is a major cause of death following conventional chemotherapy and radiation for children and adults with malignant brain tumors. It is imperative to find novel options to target therapy-resistant brain tumor populations to save lives. We propose a novel platform providing a prognostic tool and a suicide gene therapy tool using engineered viruses.

It involves targeting freshly biopsied cells from brain tumor patients with our strategy in combination with standard therapy to predict risk of patients developing relapse and a gene therapy suicide tool to remove cells causing relapse. Previous suicide gene therapies have only used viruses hitting dividing tumor cells.

Our strategy will use an enigneered virus targeting non-dividing tumor cells that we know escape standard therapy.

After removing the tumor bulk using standard treatment, we propose to use our virus with a marker for diagnostic purposes or a with a suicide gene that will be activated by a prodrug to eradicate therapy-resistant cells.

Prodrug administration before recurrence will eliminate relapsed cells once they start dividing and become dangerous.The impact of our strategy will be high, providing health care professionals with a better tool to identify patients at high risk of developing recurrence.

Such patients can receive a better, more tailored treatment that will not only increase their chance of survival but also reduce their time under hospital care and rehabilitation. We protected our strategy with a filed patent and assessed our regulatory needs. We completed a market analysis to evaluate market size and potential benefit for cancer patients.

We have disclosed competitors but also potential collaborators that can cofinance and move our strategy forward to in vitro diagnostic device registration and initial clinical trials.

In our proposal we will apply for funding covering lab work to test efficacy and safety, help with registration and negotitation strategies.

All Grantees

Uppsala Universitet Researchintellectual Property Ab; Uppsala Universitet

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant